Scientists at the National Institutes of Health (NIH) have found that two common types of hormone therapy may alter breast cancer risk in women before age 55. Researchers discovered that women treated with unopposed estrogen hormone therapy (E-HT) were less likely to develop the disease than those who did not use hormone therapy. They also found that women treated with estrogen plus progestin hormone therapy (EP-HT) were more likely to develop breast cancer than women who did not use hormone therapy. Together, these results could help to guide clinical recommendations for hormone therapy use among younger women.

Preliminary data from the ESHRE European IVF Monitoring (EIM) Consortium reveals a steady and progressive rise in the use of Assisted Reproductive Technology (ART). In 2022, a total of 960,347 ART treatment cycles were reported by 1,371 clinics across 39 European countries, a 15.6% reduction from the 1,137,177 cycles reported in 2021.

The research revealed widespread disruptions in the activity of genes responsible for early embryonic genome activation, metabolic processes, epigenetic regulation, and chromatin structure in embryos from women with PCOS.